CUSIP NO. 19249H103 |
13D |
Page 1 of 14 |
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(RULE 13d-101)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT TO RULE 13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT
TO RULE 13d-2(a)
(Amendment No. _____)*
Coherus BioSciences, Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
19249H103
(CUSIP Number)
Nathalie Auber
Sofinnova Ventures, Inc.
3000 Sand Hill Road, Bldg 4, Suite 250
Menlo Park, CA 94025
(650) 681-8420
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
COPY TO:
Linda Daley, Esq.
c/o Gunderson Dettmer Stough Villeneuve
Franklin & Hachigian, LLP
1200 Seaport Blvd., Redwood City, CA 94063
(650) 463-5243
November 6, 2014
(Date of Event Which Requires Filing of
This Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨
Note: Schedules filed in paper format shall
include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom
copies are to be sent.
*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for
any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
This information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).
CUSIP NO. 19249H103 | 13D | Page 2 of 14 |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only).
Sofinnova Venture Partners VII, L.P. (“SVP VII”)
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x
|
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS |
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
2,557,759 shares, except that Sofinnova Management
VII, L.L.C. (“SM VII”), the general partner of SVP VII, may be deemed to have sole voting power, and Dr. Michael F.
Powell (“Powell”), Dr. James I. Healy (“Healy”) and Eric P. Buatois (“Buatois”), the managing
members of SM VII, may be deemed to have shared power to vote these shares. |
8 |
SHARED VOTING POWER
See response to row 7.
|
9 |
SOLE DISPOSITIVE POWER
2,557,759 shares, except that SM VII, the general partner of
SVP VII, may be deemed to have sole dispositive power and Powell, Healy and Buatois, the managing members of SM VII, may be deemed
to have shared power to dispose of these shares.
|
10 |
SHARED DISPOSITIVE POWER
See response to row 9.
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
2,557,759 |
12 |
CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
7.9% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
PN |
|
|
CUSIP NO. 19249H103 | 13D | Page 3 of 14 |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only).
Sofinnova Management VII, L.L.C. (“SM VII”) |
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) |
(a) ¨
(b) x |
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS |
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
Delaware |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
2,557,759 shares, all of which are owned directly by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Powell, Healy and Buatois, the managing members
of SM VII, may be deemed to have shared power to vote these shares.
|
8 |
SHARED VOTING POWER
See response to row 7.
|
9 |
SOLE DISPOSITIVE POWER
2,557,759 shares, all of which are owned directly by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Powell, Healy and Buatois, the managing
members of SM VII, may be deemed to have shared dispositive power over these shares.
|
10 |
SHARED DISPOSITIVE POWER
See response to row 9.
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
2,557,759 |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
7.9% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
OO |
|
|
CUSIP NO. 19249H103 | 13D | Page 4 of 14 |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only).
Dr. Michael F. Powell (“Powell”)
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x
|
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS |
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
U.S. citizen |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
-0-
|
8 |
SHARED VOTING POWER
2,557,759 shares, all of which are directly owned by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Powell, a managing member of SM VII, may be
deemed to have shared voting power to vote these shares.
|
9 |
SOLE DISPOSITIVE POWER
-0-
|
10 |
SHARED DISPOSITIVE POWER
2,557,759 shares, all of which are directly owned by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Powell, a managing member of SM VII,
may be deemed to have shared power to dispose of these shares.
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
2,557,759 |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
7.9% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
IN |
|
|
CUSIP NO. 19249H103 | 13D | Page 5 of 14 |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only).
Dr. James I. Healy (“Healy”)
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x
|
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS |
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
U.S. citizen |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
47 shares.
|
8 |
SHARED VOTING POWER
2,557,759 shares, all of which are directly owned by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Healy, a managing member of SM VII and a director
of the Issuer, may be deemed to have shared voting power to vote these shares.
|
9 |
SOLE DISPOSITIVE POWER
47 shares.
|
10 |
SHARED DISPOSITIVE POWER
2,557,759 shares, all of which are directly owned by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Healy, a managing member of SM VII and
a director of the Issuer, may be deemed to have shared power to dispose of these shares.
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
2,557,806 |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
7.9% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
IN |
|
|
CUSIP NO. 19249H103 | 13D | Page 6 of 14 |
1 |
NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (Entities Only).
Eric P. Buatois (“Buatois”)
|
2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) ¨
(b) x
|
3 |
SEC USE ONLY |
4 |
SOURCE OF FUNDS |
WC |
5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS
REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) |
¨ |
6 |
CITIZENSHIP OR PLACE OF ORGANIZATION |
U.S. permanent resident |
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY EACH REPORTING
PERSON
WITH |
7 |
SOLE VOTING POWER
-0-
|
8 |
SHARED VOTING POWER
2,557,759 shares, all of which are directly owned by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole voting power, and Buatois, a managing member of SM VII, may
be deemed to have shared voting power to vote these shares.
|
9 |
SOLE DISPOSITIVE POWER
-0-
|
10 |
SHARED DISPOSITIVE POWER
2,557,759 shares, all of which are directly owned by SVP VII.
SM VII, the general partner of SVP VII, may be deemed to have sole dispositive power, and Buatois, a managing member of SM VII,
may be deemed to have shared power to dispose of these shares.
|
11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
2,557,759 |
12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions) |
¨ |
13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) |
7.9% |
14 |
TYPE OF REPORTING PERSON (See Instructions) |
IN |
|
|
CUSIP NO. 19249H103 | 13D | Page 7 of 14 |
Statement on Schedule 13D
This Statement on Schedule 13D relates
to the beneficial ownership of common stock, par value $0.0001 per share (“Common Stock”), of Coherus BioSciences,
Inc., a Delaware corporation (“Issuer”). This Schedule 13D is being filed by Sofinnova Venture Partners VII, L.P.,
a Delaware limited partnership (“SVP VII”), Sofinnova Management VII, L.L.C., a Delaware limited liability company
(“SM VII”), Dr. Michael F. Powell (“Powell”), Dr. James I. Healy (“Healy”), and Eric P. Buatois
(“Buatois” and collectively with SVP VII, SM VII, Powell, and Healy, “Reporting Persons”).
ITEM 1. SECURITY AND ISSUER.
(a) The class of
equity securities to which this statement relates is the Common Stock of the Issuer.
(b) The Issuer’s
principal executive offices are located at 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065.
ITEM 2. IDENTITY AND BACKGROUND.
(a) The persons
and entities filing this Schedule 13D are SVP VII, SM VII, Powell, Healy, and Buatois. SM VII, the general partner of SVP VII,
may be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by SVP VII. Healy may
be deemed to have sole power to vote and sole power to dispose of shares of the Issuer directly owned by Healy.
(b) The address
of the principal place of business for each of the Reporting Persons is c/o Sofinnova Ventures, 3000 Sand Hill Road, Bldg 4, Suite
250, Menlo Park, California 94025.
(c) The principal
occupation of each of the Reporting Persons is the venture capital investment business. The principal business of SVP VII is to
make investments in private and public companies, and the principal business of SM VII is to serve as the general partner of SVP
VII. Powell, Healy and Buatois are the managing members of SM VII. Healy is a director of the Issuer.
(d) During the last
five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar
misdemeanors).
(e) During the last
five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations
of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to
such laws.
(f) SVP VII is a
Delaware limited partnership. SM VII is a Delaware limited liability company. Powell and Healy are U.S. citizens. Buatois is a
U.S. permanent resident.
ITEM 3. SOURCE AND AMOUNT OF FUNDS
OR OTHER CONSIDERATION.
In February 2014, in
consideration of the Issuer’s acquisition of InteKrin Therapeutics, Inc., of which SVP VII and Healy were shareholders, the
Issuer issued 384,393 shares of Series B convertible preferred stock of the Issuer to SVP VII and 47 shares of Series B convertible
preferred stock of the Issuer to Healy. In connection with such acquisition, the Issuer assumed
a convertible note of InteKrin payable to SVP VII, which was concurrently paid off by issuing 243,841 shares of Series B
convertible preferred stock of the Issuer with a fair value of $1.0 million, as valued in such merger.
In February 2014, SVP
VII purchased from a third party an aggregate of 716,857 shares of Series B convertible preferred stock of the Issuer for a purchase
price of $6.97 per share, or $4,999,999 in the aggregate.
CUSIP NO. 19249H103 | 13D | Page 8 of 14 |
On
February 12, 2014, Healy was granted an option to purchase up to 29,994 shares of the Issuer’s Common Stock. A portion of
the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows:
the underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years
measured from February 12, 2014, subject to Healy’s continued service relationship with the Issuer on each such vesting date.
In March 2014, SVP VII
purchased from a third party an aggregate of 134,973 shares of Common Stock for a purchase price of $1.67 per share, or $225,000
in the aggregate.
In May 2014, SVP VII
purchased from a third party an aggregate of 501,799 shares of Series B convertible preferred stock of the Issuer for a purchase
price of $8.75 per share, or $4,391,625 in the aggregate.
In May 2014, SVP VII
acquired from the Issuer an aggregate of 149,970 shares of Series C convertible preferred stock of the Issuer at a price of $10.002
per share, or $1,500,000 in the aggregate.
On
October 10, 2014, the Issuer’s Board of Directors approved the filing of an amendment to the Issuer’s certificate of
incorporation to reflect a 1-for-1.667 reverse stock split (the “Reverse Stock Split”). All information in this Schedule
13D related to the number of shares, price per share and per share amounts of stock, and shares issuable under stock options and
warrants have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented.
In connection with the
Issuer’s initial public offering of Common Stock, which closed on November 12, 2014 (“Offering”), the shares
of Series B convertible preferred stock previously acquired by certain of the Reporting Persons were converted into Common Stock
on a 1 for 1 basis.
In connection with the
Offering, the shares of Series C convertible preferred stock previously acquired by certain of the Reporting Persons were converted
into Common Stock on a 1 for 1 basis.
SVP VII purchased 425,926
shares of the Common Stock at $13.50 per share in the Offering, or $5,750,001 in the aggregate.
The source
of the funds for all purchases and acquisitions by the Reporting Persons was from working capital.
No part of the purchase price was borrowed by any Reporting
Person for the purpose of acquiring any securities discussed in this Item 3.
ITEM 4. PURPOSE OF TRANSACTION.
The Reporting Persons
hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may,
from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of the shares of Common
Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common
Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake
will be dependent upon the Reporting Persons’ review of numerous factors, including, among other things, the price levels
of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition,
operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments.
Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of
the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
CUSIP NO. 19249H103 | 13D | Page 9 of 14 |
ITEM 5. INTEREST IN SECURITIES
OF THE ISSUER.
(a,b) Regarding
aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. Regarding percentage beneficial ownership,
see Row 13 of the cover page of each Reporting Person. Regarding sole power to vote shares, see Row 7 of the cover page of each
Reporting Person. Regarding shared power to vote shares, see Row 8 of the cover page of each Reporting Person. Regarding sole power
to dispose of shares, see Row 9 of the cover page of each Reporting Person. Regarding shared power to dispose of shares, see Row
10 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated based upon
32,559,351 shares of Common Stock outstanding immediately after the Offering.
(c) Except as set
forth in Item 3 above, the Reporting Persons have not effected any transaction in the Common Stock of the Issuer during the past
60 days.
(d) Under certain
circumstances set forth in the limited partnership agreement of SVP VII, the general partner and limited partners of SVP VII may
be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity
of which they are a partner.
(e) Not applicable.
ITEM
6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.
In connection with the
acquisition of the preferred stock of the Issuer, the Reporting Persons and certain other investors are entitled to the registration
of their shares, including demand and piggyback registration rights, as more fully described in the Issuer’s Registration
Statement on Form S-1, filed with the SEC on September 25, 2014 (the “Prospectus”) and incorporated herein by reference.
In connection with the
acquisition of the preferred stock of the Issuer, the Reporting Persons and certain other investors entered into a voting agreement,
entitling such parties to designate a director to the Issuer’s board of directors, and a right of first refusal and co-sale
agreement, providing for rights of first refusal and co-sale relating to the shares of Common Stock held by certain key holders
of the Common Stock. Each such voting agreement and such right of first refusal and co-sale agreement automatically terminated
upon the closing of the Offering Each such voting agreement and such right of first refusal and co-sale agreement is more fully
described in the Prospectus and incorporated herein by reference.
Healy, in his capacity
as a director of the Issuer, and along with the other directors of the Issuer, entered into an Indemnification Agreement with the
Issuer, as more fully described in the Prospectus and incorporated herein by reference.
On
February 12, 2014, Healy was granted an option to purchase up to 29,994 shares of the Issuer’s Common Stock. A portion of
the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows:
the underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years
measured from February 12, 2014, subject to Healy’s continued service relationship with the Issuer on each such vesting date.
The Issuer’s stock option plans are more fully described in the Prospectus and incorporated herein by reference.
In connection with the
Issuer’s initial public offering, the Reporting Persons and certain other persons entered into a lock-up agreement and agreed,
subject to certain exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or
indirectly, any shares of Common Stock or any securities convertible into or exchangeable for shares of Common Stock, or enter
into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of any shares
of Common Stock or such other securities, without the prior written consent of J.P. Morgan
Securities LLC and Credit Suisse Securities (USA) LLC for a period of 180 days from the date of the Prospectus, subject
to certain exceptions. Such lock-up period is more fully described in the Prospectus and incorporated herein by reference.
CUSIP NO. 19249H103 | 13D | Page 10 of 14 |
ITEM 7. MATERIAL TO BE FILED AS
EXHIBITS.
EXHIBIT A |
Agreement of Joint Filing. |
EXHIBIT B |
Power of Attorney. |
EXHIBIT C |
Form of Indemnification Agreement for Directors and Officers, the form is incorporated herein by reference to Exhibit 10.13 to the Issuer’s Registration Statement on Form S-1, filed with the SEC on September 25, 2014. |
EXHIBIT D |
Form of Lock-Up Agreement entered into by and among the Issuer, the underwriters and certain others, the form is incorporated by reference to Exhibit A to Exhibit 1.1 to the Issuer’s Registration Statement on Form S-1 filed with the SEC on September 25, 2014. |
CUSIP NO. 19249H103 | 13D | Page 11 of 14 |
SIGNATURES
After reasonable inquiry
and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: November 14, 2014
|
SOFINNOVA VENTURE PARTNERS VII, L.P., a Delaware Limited Partnership |
|
|
|
|
|
By: |
SOFINNOVA MANAGEMENT VII, L.L.C., a Delaware Limited Liability Company |
|
|
Its: |
General Partner |
|
|
|
|
|
|
By: |
/s/ Nathalie Auber |
|
|
|
Nathalie Auber |
|
|
|
Attorney-in-Fact |
|
|
|
|
|
|
|
|
|
|
SOFINNOVA MANAGEMENT VII, a Delaware Limited Liability Company |
|
|
|
|
|
|
By: |
/s/ Nathalie Auber |
|
|
|
Nathalie Auber |
|
|
|
Attorney-in-Fact |
|
|
|
|
|
|
|
|
|
|
DR. JAMES I. HEALY |
|
|
DR. MICHAEL F. POWELL |
|
|
ERIC P. BUATOIS |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Nathalie Auber |
|
|
|
Nathalie Auber |
|
|
|
Attorney-in-Fact |
|
|
|
|
|
*Signed pursuant to a Power of Attorney
already on file with the appropriate agencies.
CUSIP NO. 19249H103 | 13D | Page 12 of 14 |
EXHIBIT INDEX
Exhibit |
|
Description |
|
|
|
A |
|
Agreement of Joint Filing. |
B |
|
Power of Attorney. |
C |
|
Form of Indemnification Agreement for Directors and Officers, the form is incorporated herein by reference to Exhibit 10.13 to the Issuer’s Registration Statement on Form S-1, filed with the SEC on September 25, 2014. |
D |
|
Form of Lock-Up Agreement entered into by and among the Issuer, the underwriters and certain others, the form is incorporated by reference to Exhibit A to Exhibit 1.1 to the Issuer’s Registration Statement on Form S-1 filed with the SEC on September 25, 2014. |
CUSIP NO. 19249H103 | 13D | Page 13 of 14 |
exhibit A
Agreement of Joint Filing
The undersigned hereby
agree that a single Schedule 13D (or any amendment thereto) relating to the Common Stock of Coherus BioSciences, Inc. shall be
filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.
Date: November 14, 2014
|
SOFINNOVA VENTURE PARTNERS VII, L.P., a Delaware Limited Partnership |
|
|
|
|
|
By: |
SOFINNOVA MANAGEMENT VII, L.L.C., a Delaware Limited Liability Company |
|
|
Its: |
General Partner |
|
|
|
|
|
|
By: |
/s/ Nathalie Auber |
|
|
|
Nathalie Auber |
|
|
|
Attorney-in-Fact |
|
|
|
|
|
|
|
|
|
|
SOFINNOVA MANAGEMENT VII, a Delaware Limited Liability Company |
|
|
|
|
|
|
By: |
/s/ Nathalie Auber |
|
|
|
Nathalie Auber |
|
|
|
Attorney-in-Fact |
|
|
|
|
|
|
|
|
|
|
DR. JAMES I. HEALY |
|
|
DR. MICHAEL F. POWELL |
|
|
ERIC P. BUATOIS |
|
|
|
|
|
|
|
|
|
|
By: |
/s/ Nathalie Auber |
|
|
|
Nathalie Auber |
|
|
|
Attorney-in-Fact |
|
|
|
|
|
CUSIP NO. 19249H103 | 13D | Page 14 of 14 |
exhibit B
Power
of Attorney
Nathalie Auber has
signed this Schedule 13D as Attorney-In-Fact. Note that copies of the applicable Power of Attorney are already on file with the
appropriate agencies.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024